Advisory Services Network LLC lifted its holdings in shares of Crispr Therapeutics AG (NASDAQ:CRSP) by 146.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 674 shares of the company’s stock after buying an additional 400 shares during the period. Advisory Services Network LLC’s holdings in Crispr Therapeutics were worth $41,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of CRSP. Nikko Asset Management Americas Inc. boosted its position in shares of Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after buying an additional 906,006 shares during the period. Orbimed Advisors LLC bought a new stake in Crispr Therapeutics during the third quarter worth approximately $21,167,000. ARK Investment Management LLC raised its holdings in Crispr Therapeutics by 6.3% during the fourth quarter. ARK Investment Management LLC now owns 2,956,635 shares of the company’s stock worth $180,074,000 after purchasing an additional 174,495 shares in the last quarter. Millennium Management LLC bought a new stake in Crispr Therapeutics during the third quarter worth approximately $4,366,000. Finally, Columbus Circle Investors bought a new stake in Crispr Therapeutics during the fourth quarter worth approximately $6,023,000. Institutional investors and hedge funds own 51.28% of the company’s stock.
NASDAQ CRSP opened at $53.03 on Friday. The stock has a market capitalization of $3.54 billion, a P/E ratio of 54.67 and a beta of 3.25. Crispr Therapeutics AG has a 1 year low of $30.83 and a 1 year high of $74.00. The business’s fifty day moving average is $56.62 and its two-hundred day moving average is $53.20.
Several brokerages recently commented on CRSP. William Blair reissued a “buy” rating on shares of Crispr Therapeutics in a report on Thursday, February 13th. Oppenheimer boosted their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, November 25th. Piper Sandler reissued a “buy” rating and set a $104.00 target price on shares of Crispr Therapeutics in a report on Thursday, February 13th. Zacks Investment Research raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 17th. Finally, Roth Capital boosted their target price on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the company’s stock. Crispr Therapeutics presently has an average rating of “Buy” and a consensus target price of $78.29.
Crispr Therapeutics Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: 52-Week High/Low Prices For Stock Selection
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.